DexCom, Inc. DXCM shares are dropping after the company reported its second-quarter financial results Thursday. Here's a look at the key figures from the report.
The Details: DexCom reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 39 cents by 10.26%.
Quarterly sales came in at $1.004 billion which missed the analyst consensus estimate of $1.036 billion by 3.13% and represents a 15.23% increase over the same period last year. U.S. revenue grew 19% and international revenue grew 7% year-over-year.
Read Also: What’s Going On With Super Micro Computer Stock?
The company also announced a $750 million share repurchase program in conjunction with second-quarter results.
“While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,” said Kevin Sayer, Dexcom’s CEO. “We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth.”
Outlook: DexCom sees third-quarter revenue in a range of $975 million to $1 billion, versus the $1.15 billion estimate, and full-year revenue in a range of $4. billion to $4.05 billion, versus the $4.33 billion estimate.
DXCM Price Action: According to Benzinga Pro, DexCom shares are down 32.92% after-hours at $72.50 at the time of publication Thursday.
Read Next:
Photo: Courtesy of DexCom, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
